Guadecitabine

Generic Name: Guadecitabine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₄N_₉O_₁₀P

CAS Number: 929901-49-5

Unique Ingredient Identifier: 2KT4YN1DP7

Background: Guadecitabine is under investigation for the treatment of Previously Treated Metastatic Colorectal Cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Phase 2

Active, not recruiting

Conditions: Metastatic Primary Central Chondrosarcoma
Locally Advanced Unresectable Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma

Interventions: Drug: Belinostat
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Decitabine and Cedazuridine
Drug: Guadecitabine
Procedure: Magnetic Resonance Imaging

First Posted Date: 2020-04-10

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT04340843

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
HaysMed, Hays, Kansas, United States

and more 36 locations

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer

Interventions: Drug: Guadecitabine
Drug: Carboplatin

First Posted Date: 2019-04-12

Last Posted Date: 2023-12-20

Lead Sponsor: Shadia Jalal, MD

Target Recruit Count: 24

Registration Number: NCT03913455

Locations: 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
IU Health Ball Memorial Cancer Center, Muncie, Indiana, United States

and more 1 locations

Guadecitabine Extension Study

Phase 2

Terminated

Conditions: Myeloid Dysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: Guadecitabine

First Posted Date: 2018-07-27

Last Posted Date: 2024-08-27

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 35

Registration Number: NCT03603964

Locations: 🇺🇸
Center for Blood Cancers, Nashville, Tennessee, United States
🇮🇹
Azienda Ospedaliera Universitaria San Martino, Genova, Italy
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 18 locations

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Phase 1

Withdrawn

Conditions: Colorectal Adenocarcinoma
Refractory Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
CpG Island Methylator Phenotype
Metastatic Microsatellite Stable Colorectal Carcinoma
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Interventions: Drug: Guadecitabine
Biological: Nivolumab

First Posted Date: 2018-07-05

Last Posted Date: 2021-04-05

Lead Sponsor: University of Southern California

Registration Number: NCT03576963

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Phase 2

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Drug: Guadecitabine

First Posted Date: 2018-03-06

Last Posted Date: 2018-11-15

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 40

Registration Number: NCT03454984

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
Hôpital St Louis, Paris, France
🇫🇷
CHU Estaing, Clermont-Ferrand, France

and more 9 locations

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Kidney Cancer
Kidney Cancer
Clear Cell Renal Cell Carcinoma

Interventions: Drug: Guadecitabine
Drug: Durvalumab

First Posted Date: 2017-10-12

Last Posted Date: 2022-02-17

Lead Sponsor: Ajjai Alva, MD

Target Recruit Count: 57

Registration Number: NCT03308396

Locations: 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸
University of Iowa Hosptials and Clinics, Iowa City, Iowa, United States
🇺🇸
Univerisity of Illinois Cancer Center, Chicago, Illinois, United States

and more 2 locations

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Gallbladder Carcinoma
Stage III Gallbladder Cancer AJCC V7
Stage IIIB Gallbladder Cancer AJCC v7
Gallbladder Adenocarcinoma, Biliary Type
Stage IIIA Hepatocellular Carcinoma AJCC v7
Stage IIIB Hepatocellular Carcinoma AJCC v7
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type
Recurrent Hepatocellular Carcinoma
Recurrent Pancreatic Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v7

Interventions: Biological: Durvalumab
Drug: Guadecitabine

First Posted Date: 2017-08-22

Last Posted Date: 2024-07-10

Lead Sponsor: University of Southern California

Target Recruit Count: 55

Registration Number: NCT03257761

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab (immunotherapy Drug) in Combination with Guadecitabine and Mocetinostat (epigenetic Drugs) for Patients with Advanced Lung Cancer.

Phase 1

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Guadecitabine
Drug: Mocetinostat

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT03220477

Locations: 🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Primary Peritoneal Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Platinum-Resistant Fallopian Tube Carcinoma

Interventions: Drug: Atezolizumab
Other: Laboratory Biomarker Analysis
Drug: Guadecitabine
Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Poly ICLC

First Posted Date: 2017-07-02

Last Posted Date: 2024-10-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT03206047

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 14 locations

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Guadecitabine

First Posted Date: 2017-06-07

Last Posted Date: 2021-11-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT03179943

Locations: 🇺🇸
USC Norris Hospital and Clinics, Los Angeles, California, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy